(-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization

Molecular and Cellular Oncology

Volumn 2, Issue 4, 2015, Pages

  LeGendre, Onica ^a,b   Breslin, Paul AS ^c,d   Foster, David A ^a,e  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CUNY   (United States)

^c the State University of New Jersey   (United States)

^d MONELL CHEMICAL SENSES CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

apoptosis; extra virgin olive oil; lysosomal membrane permeabilization; necrosis; oleocanthal

Indexed keywords

EID: 85045725832     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.1080/23723556.2015.1006077     Document Type: Article

References (40)

1. Giacosa A, Barale R, Bavaresco L, Gatenby P, Gerbi V, Janssens J, Johnston B, Kas K, La Vecchia C, Mainguet P, et al. Cancer prevention in Europe: the Mediterranean diet as a protective choice. Eur J Cancer Prev 2013; 22:90–5; PMID:22644232; http://dx.doi.org/10.1097/CEJ.0b013e328354d2d7
2. Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, Fernandez-Gutierrez A, Segura-Carretero A. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 2007; 7:80; PMID:17490486; http://dx.doi.org/10.1186/1471-2407-7-80
3. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, Lee CH, Smith AB, Breslin PA. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 2005; 437:45–6; PMID:16136122; http://dx.doi.org/10.1038/437045a
4. Busnena BA, Foudah AI, Melancon T, El Sayed KA. Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer. Bioorg Med Chem 2013; 21:2117–27; PMID:23403296; http://dx.doi.org/10.1016/j.bmc.2012.12.050
5. Elnagar AY, Sylvester PW, El Sayed KA. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med 2011; 77:1013–9; PMID:21328179; http://dx.doi.org/10.1055/s-0030-1270724
6. Monti MC, Margarucci L, Riccio R, Casapullo A. Modulation of tau protein fibrillization by oleocanthal. J Nat Prod 2012; 75:1584–8; PMID:22988908; http://dx.doi.org/10.1021/np300384h
7. Scotece M, Gomez R, Conde J, Lopez V, Gomez-Reino JJ, Lago F, Smith AB, 3rd, Gualillo O. Oleocanthal inhibits proliferation and MIP-1a expression in human multiple myeloma cells. Curr Med Chem 2013; 20:2467–75; PMID:23521677; http://dx.doi.org/10.2174/0929867311320190006
8. Pitt J, Roth W, Lacor P, Smith AB, 3rd, Blankenship M, Velasco P, De Felice F, Breslin P, Klein WL. Alzheimer's-associated Ab oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol 2009; 240:189–97; PMID:19631677; http://dx.doi.org/10.1016/j.taap.2009.07.018
9. Zhuang S, Kinsey GR, Yan Y, Han J, Schnellmann RG. Extracellular signal-regulated kinase activation mediates mitochondrial dysfunction and necrosis induced by hydrogen peroxide in renal proximal tubular cells. J Pharmacol Exp Ther 2008; 325:732–40; PMID:18339970; http://dx.doi.org/10.1124/jpet.108.136358
10. Salvesen GS. Caspases: opening the boxes and interpreting the arrows. Cell Death Differ 2002; 9:3–5; PMID:11803369; http://dx.doi.org/10.1038/sj.cdd.4400963
11. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009; 46:497–510; PMID:19505876; http://dx.doi.org/10.1136/jmg.2009.066944
12. Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor b-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002; 22:8184–98; PMID:12417722; http://dx.doi.org/10.1128/MCB.22.23.8184-8198.2002
13. Ho A, Dowdy SF. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 2002; 12:47–52; PMID:11790554; http://dx.doi.org/10.1016/S0959-437X(01)00263-5
14. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991; 67:293–302; PMID:1655277; http://dx.doi.org/10.1016/0092-8674(91)90181-W
15. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 1993; 13:6501–8; PMID:8413249
16. Schmitz NM, Hirt A, Aebi M, Leibundgut K. Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol 2006; 169:1074–9; PMID:16936279; http://dx.doi.org/10.2353/ajpath.2006.051137
17. Kalan S, Matveyenko A, Loayza D. LIM protein ajuba participates in the repression of the ATR-mediated DNA damage response. Front Genet 2013; 4:95; PMID:23755068; http://dx.doi.org/10.3389/fgene.2013.00095
18. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994; 54:6167–75; PMID:7954463
19. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res 2003; 283:1–16; PMID:12565815; http://dx.doi.org/10.1016/S0014-4827(02)00027-7
20. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005; 73:1907–16; PMID:15784530; http://dx.doi.org/10.1128/IAI.73.4.1907-1916.2005
21. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008; 27:6434–51; PMID:18955971; http://dx.doi.org/10.1038/onc.2008.310
22. 2 is a consequence of lysosomal rupture. Biochem J 2001; 356:549–55; PMID:11368784; http://dx.doi.org/10.1042/0264-6021:3560549
23. Kirkegaard T, Roth AG, Petersen NH, Mahalka AK, Olsen OD, Moilanen I, Zylicz A, Knudsen J, Sandhoff K, Arenz C, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010; 463:549–53; PMID:20111001; http://dx.doi.org/10.1038/nature08710
24. Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 2013; 24:379–93; PMID:24029234; http://dx.doi.org/10.1016/j.ccr.2013.08.003
25. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005; 5:886–97; PMID:16239905; http://dx.doi.org/10.1038/nrc1738
26. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004; 23:2881–90; PMID:15077151; http://dx.doi.org/10.1038/sj.onc.1207512
27. Kolter T, Sandhoff K. Lysosomal degradation of membrane lipids. FEBS Lett 2010; 584:1700–12; PMID:19836391; http://dx.doi.org/10.1016/j.febslet.2009.10.021
28. Dridi S, Decuypere E, Buyse J. Cerulenin upregulates heat shock protein-70 gene expression in chicken muscle. Poult Sci 2013; 92:2745–53; PMID:24046423; http://dx.doi.org/10.3382/ps.2013-03242
29. Wattiaux R, Jadot M, Warnier-Pirotte MT, Wattiaux-De Coninck S. Cationic lipids destabilize lysosomal membrane in vitro. FEBS Lett 1997; 417:199–202; PMID:9395295; http://dx.doi.org/10.1016/S0014-5793(97)01283-0
30. Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 2009; 21:836–46; PMID:19385042; http://dx.doi.org/10.1016/j.cellsig.2009.01.026
31. Oninla VO, Breiden B, Babalola JO, Sandhoff K. Acid sphingomyelinase activity is regulated by membrane lipids and facilitates cholesterol transfer by NPC2. J Lipid Res 2014; 55:2606–19; PMID:25339683; http://dx.doi.org/10.1194/jlr.M054528
32. Linke T, Wilkening G, Lansmann S, Moczall H, Bartelsen O, Weisgerber J, Sandhoff K. Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol Chem 2001; 382:283–90; PMID:11308026; http://dx.doi.org/10.1515/BC.2001.035
33. Burke JR, Deshong AJ, Pelton JG, Rubin SM. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem 2010; 285:16286–93; PMID:20223825; http://dx.doi.org/10.1074/jbc.M110.108167
34. Flemington EK, Speck SH, Kaelin WG, Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1993; 90:6914–8; PMID:8346196; http://dx.doi.org/10.1073/pnas.90.15.6914
35. Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Hoyer-Hansen M, Weber E, Multhoff G, Rohde M, Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004; 200:425–35; PMID:15314073; http://dx.doi.org/10.1084/jem.20040531
36. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6:764–75; PMID:16990854; http://dx.doi.org/10.1038/nrc1949
37. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5:2592–601; PMID:17106261; http://dx.doi.org/10.4161/cc.5.22.3448
38. Akl MR, Ayoub NM, Mohyeldin MM, Busnena BA, Foudah AI, Liu YY, Sayed KA. Olive phenolics as c-Met inhibitors: (-)-oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS One 2014; 9:e97622; PMID:24849787; http://dx.doi.org/10.1371/journal.pone.0097622.
39. Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res 2013; 11:474–81; PMID:23443316; http://dx.doi.org/10.1158/1541-7786.MCR-12-0679
40. LeGendre O, Sookdeo A, Foster DA. BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition. Oncology Lett 2014; 7:1165–8